Biotech

China is Closing the Biopharma Innovation Gap 

The Chinese Communist Party’s strategy to move up the biopharma value chain is showing results, risking deeper U.S. dependencies on China for medicines and eroding the U.S. drug development pipeline, especially for small startups. 

19 November 2026

Washington, D.C. – Today, the National Security Commission on Emerging Biotechnology (NSCEB) released new analysis on the CCP’s progress towards dominance at all levels of the global biopharmaceutical value chain. The NSCEB found that drug development deals, including licensing deals, are driving not just capital but commercialization know-howback into the Chinese biotech ecosystem, creating a flywheel effect that advances China’s goal to control the global pharmaceutical supply chain.   

NSCEB found that U.S. and global pharmaceutical companies are making deals with Chinese biotechnology companies earlier in the drug discovery process, including before initial clinical trials, signaling a growing trustin China’s innovation engine. The terms of the deals are also increasingly favoring the Chinese biotech startups or licensors, moving from single-asset agreements to multi-asset or platform co-development and co-commercialization deals.   

“The CCP seeks dominance in biotechnology as a source of economic power and geopolitical advantage, and Beijing has spent decades pursuing a deliberate strategy to achieve that at all levels of the value chain,” said NSCEB Executive Director Caitlin Frazer. “US-China pharma deals are starting to favor the Chinese startups, which risks eroding biotech R&D in the US. This trend should be alarming for policymakers.”  

Read the new analysis here. 

 

Additional Details

In its April 2025 report to Congress, the NSCEB posed an alarming hypothetical in which the CCP leveraged Americans’ access to lifesaving medicines to gain geopolitical advantage. Although that was fiction, China’s grip on supply chains and its exponential growth in biopharma innovation are coming closer to making that scenario a reality.  

The Chinese government’s September 2026 five-year plan for the pharmaceutical industry details a strategy to accelerate its control of the biotechnology sector, and with licensing deals between Chinese biotechnology companies and U.S.-based pharmaceutical companies rapidly rising, the window to act is closing swiftly.  

 

About NSCEB: The National Security Commission on Emerging Biotechnology is a time-limited, high-impact legislative branch advisory entity whose purpose is to advance and secure biotechnology, biomanufacturing, and associated technologies for U.S. national security and to prepare the United States for the bioindustrial revolution. The Commission published a comprehensive report in April 2025, including recommendations for action by Congress and the federal government. The bipartisan Commission is composed of Congressionally-appointed Commissioners with members from both the Senate and the House of Representatives as well as experts from industry, academia, and government. For more information about the Commission and to view the report, visit: biotech.senate.gov.   

Contacts:  

NSCEB: press@biotech.senate.gov